Get the Stockscreener App
2.51
15.67%
0.34
After Hours:
2.45
-0.06
-2.39%
Sab Biotherapeutics Inc stock is traded at $2.51, with a volume of 434.69K.
It is up +15.67% in the last 24 hours and down -2.71% over the past month.
SAB Biotherapeutics Inc is a clinical stage biopharmaceutical company focused on the development and commercialization of a portfolio of products from its proprietary immunotherapy platform to produce fully targeted human polyclonal antibodies, without using human plasma or serum. The company's novel DiversitAb platform enables the rapid production of large amounts of targeted human polyclonal antibodies, leveraging transchromosomic cattle (Tc Bovine) that have been genetically designed to produce human antibodies (immunoglobulin G) rather than bovine in response to an antigen. Animal antibodies have been made in rabbits, sheep and horses.
See More
Previous Close:
$2.17
Open:
$2.25
24h Volume:
434.69K
Relative Volume:
0.30
Market Cap:
$26.13M
Revenue:
-
Net Income/Loss:
$-45.57M
P/E Ratio:
-0.3984
EPS:
-6.3
Net Cash Flow:
$-38.56M
1W Performance:
+9.61%
1M Performance:
-2.71%
6M Performance:
+74.91%
1Y Performance:
-9.06%
1-Day Range:
$2.10
$2.54
1-Week Range:
$2.10
$2.54
52-Week Range:
$1.00
$6.60
Sab Biotherapeutics Inc Stock (SABS) Company Profile
Name
Sab Biotherapeutics Inc
Sector
Industry
Phone
305-845-2813
Address
777 W 41ST ST, MIAMI BEACH
Compare SABS with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
SABS
Sab Biotherapeutics Inc
|
2.51 | 22.59M | 0 | -45.57M | -38.56M | -6.30 |
|
VRTX
Vertex Pharmaceuticals Inc
|
416.81 | 104.76B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
481.67 | 63.06B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
578.05 | 60.32B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
843.66 | 51.55B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
165.76 | 34.49B | 398.11M | -1.03B | -868.57M | -5.7032 |
Sab Biotherapeutics Inc Stock (SABS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-17-25 | Initiated | Leerink Partners | Outperform |
| May-14-25 | Resumed | H.C. Wainwright | Buy |
| Oct-09-24 | Initiated | Craig Hallum | Buy |
| Aug-28-24 | Initiated | Oppenheimer | Outperform |
| Nov-05-21 | Initiated | Chardan Capital Markets | Buy |
Sab Biotherapeutics Inc Stock (SABS) Latest News
Tick level data insight on SAB Biotherapeutics Inc. volatilityWeekly Trade Recap & Intraday High Probability Alerts - newser.com
Analyst Upgrade: Is SAB Biotherapeutics Inc. stock ready for breakoutJuly 2025 Rallies & Stepwise Entry and Exit Trade Signals - Trung tâm Dự báo KTTV quốc gia
Will SAB Biotherapeutics Inc. stock deliver consistent dividendsJuly 2025 Sentiment & Fast Momentum Entry Tips - newser.com
Will SAB Biotherapeutics Inc. Equity Warrant stock benefit from sector rotationWeekly Market Outlook & Safe Entry Trade Signal Reports - newser.com
Can SAB Biotherapeutics Inc. Equity Warrant stock resist sector downturnsQuarterly Profit Summary & Real-Time Stock Movement Alerts - newser.com
How sustainable is SAB Biotherapeutics Inc. Equity Warrant stock dividend payoutPortfolio Update Report & Free Daily Entry Point Trade Alerts - newser.com
How SAB Biotherapeutics Inc. Equity Warrant stock performs in interest rate cyclesJuly 2025 Patterns & Safe Entry Momentum Tips - newser.com
Will breakout in SAB Biotherapeutics Inc. lead to full recoveryMarket Rally & Fast Exit Strategy with Risk Control - newser.com
SAB Biotherapeutics (NASDAQ:SABS) Receives “Sell (E+)” Rating from Weiss Ratings - Defense World
Will SAB Biotherapeutics Inc. Equity Warrant stock benefit from upcoming earnings reportsInflation Watch & Consistent Return Investment Signals - newser.com
Can SAB Biotherapeutics Inc. stock sustain institutional interestMarket Sentiment Summary & Consistent Growth Equity Picks - newser.com
How to build a custom watchlist for SAB Biotherapeutics Inc. Equity WarrantPortfolio Risk Summary & Short-Term Swing Trade Alerts - newser.com
Will SAB Biotherapeutics Inc. stock see PE expansion2025 Market WrapUp & Precise Buy Zone Identification - newser.com
What technical models suggest about SAB Biotherapeutics Inc. Equity Warrant’s comebackPortfolio Update Summary & Verified High Yield Trade Plans - newser.com
Why retail investors pile into SAB Biotherapeutics Inc. stockEarnings Growth Summary & Growth-Oriented Investment Plans - newser.com
SAB Biotherapeutics Inc Equity Warrant Stock Analysis and ForecastStochastic Oscillator Alerts & Low Entry Cost Investments - earlytimes.in
How to monitor SAB Biotherapeutics Inc. with trend dashboards2025 Trading Volume Trends & Entry Point Confirmation Signals - newser.com
Is SAB Biotherapeutics Inc. stock bottoming outJuly 2025 Snapshot & Free High Accuracy Swing Entry Alerts - newser.com
SAB Biotherapeutics Inc. Equity Warrant stock outlook for YEARWeekly Trade Report & AI Powered Buy/Sell Recommendations - newser.com
Is SAB Biotherapeutics Inc a good long term investmentInsider Trading Activity & Big Profit Low Investment - earlytimes.in
Should you wait for a breakout in SAB Biotherapeutics Inc.Quarterly Earnings Report & Risk Controlled Daily Plans - newser.com
Using Ichimoku Cloud for SAB Biotherapeutics Inc. Equity Warrant technicalsWeekly Trade Recap & Precise Buy Zone Identification - newser.com
How to track smart money flows in SAB Biotherapeutics Inc. Equity WarrantJuly 2025 EndofMonth & Weekly Top Gainers Alerts - newser.com
SABSW Stock Institutional Owners - Quiver Quantitative
Is SAB Biotherapeutics Inc. stock reversal real or fake2025 Market Outlook & Risk Managed Investment Strategies - newser.com
COMMODORE CAPITAL LP Acquires Significant Stake in SAB Biotherap - GuruFocus
RA CAPITAL MANAGEMENT, L.P. Acquires Significant Stake in SAB Bi - GuruFocus
Will SAB Biotherapeutics Inc. Equity Warrant stock recover after recent dropWeekly Trade Summary & Verified Short-Term Trading Plans - newser.com
Will SAB Biotherapeutics Inc. Equity Warrant bounce back from current supportJuly 2025 Review & Daily Technical Forecast Reports - newser.com
How to interpret RSI for SAB Biotherapeutics Inc. stockTrade Volume Report & Real-Time Sentiment Analysis - newser.com
Advanced analytics toolkit walkthrough for SAB Biotherapeutics Inc.Market Growth Summary & Real-Time Chart Breakout Alerts - newser.com
Is SAB Biotherapeutics Inc. stock entering bullish territoryWeekly Risk Report & Weekly Top Gainers Trade List - newser.com
Published on: 2025-10-09 02:46:01 - newser.com
What drives SAB Biotherapeutics Inc stock priceIPO Market Watch & High Return Trading Ideas - earlytimes.in
Can technical indicators confirm SAB Biotherapeutics Inc.’s reversalEarnings Recap Summary & Risk Managed Investment Entry Signals - newser.com
Institutional scanner results for SAB Biotherapeutics Inc. Equity Warrant2025 Historical Comparison & Reliable Intraday Trade Plans - newser.com
Strategies to average down on SAB Biotherapeutics Inc. Equity WarrantWeekly Loss Report & Community Verified Swing Trade Signals - newser.com
Will SAB Biotherapeutics Inc. see short term momentumDollar Strength & Fast Entry High Yield Stock Tips - newser.com
Full technical analysis of SAB Biotherapeutics Inc. stockJuly 2025 Decliners & Target Return Focused Picks - newser.com
Will a bounce in SAB Biotherapeutics Inc. Equity Warrant offer an exit2025 Pullback Review & Expert Approved Momentum Ideas - newser.com
Using data filters to optimize entry into SAB Biotherapeutics Inc.Entry Point & Advanced Technical Signal Analysis - newser.com
Sab Biotherapeutics Inc Stock (SABS) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.84%
0.50%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):